For Medspa Owners / Regulations

What you can prescribe.

State-by-state GLP-1 compounding rules, 503A vs 503B sourcing, FDA shortage list implications, and medical director requirements. Updated April 2026.

Key Facts

Shortage-tied

503A/503B compounding of semaglutide & tirzepatide is permissible only while on the FDA shortage list.

State-specific

Medical director requirements, telemedicine rules, and pharmacy sourcing rules vary by state.

No DEA

needed for GLP-1 alone. Required for Schedule III–V ancillaries like phentermine.

503A vs 503B explained

503A pharmacies are state-licensed compounding pharmacies operating under section 503A of the FD&C Act. They compound patient-specific prescriptions, cannot batch-manufacture for office use, and are regulated primarily by state pharmacy boards. 503B outsourcing facilities register directly with the FDA, operate under cGMP, and can produce bulk compounded medications for office-use dispensing. 503B-sourced GLP-1 programs typically have stronger quality assurance and documented sterility testing.

FDA shortage list: what it means for your business

Section 503A of the FD&C Act allows compounding of drugs on the FDA drug shortage list. When a medication comes off the shortage list, bulk compounding for weight loss becomes legally restricted in most states. Patient-specific compounding with a clinically meaningful difference (dose strength, dosage form, or added ingredient with medical necessity) may remain permissible but requires careful documentation.

Medical director requirements

State requirements for physician oversight of NP-led GLP-1 programs vary widely. Full-practice-authority states (e.g., AZ, CO, OR, WA) allow NPs to practice independently. Reduced-practice states (e.g., NY, IL) require collaborative practice agreements. Restricted-practice states (e.g., TX, FL) require formal physician supervision with specific ratios and chart review requirements.

Telemedicine across state lines

Prescribers must hold an active license in the state where the patient is physically located at the time of the encounter. The Interstate Medical Licensure Compact accelerates multi-state licensing but does not eliminate it. Nurse Licensure Compact covers NPs in most (but not all) states. Audit your state licensure coverage quarterly.

Frequently asked

Can I still compound semaglutide in 2026? +
503A and 503B compounding of semaglutide for weight loss is legally permissible only when the FDA-approved product is on the official FDA drug shortage list, or when the compounded formulation differs meaningfully from the commercial product (a patient-specific clinical justification). The shortage status changes; verify with the FDA drug shortage database before dispensing.
What is the difference between 503A and 503B? +
503A pharmacies compound patient-specific prescriptions under state pharmacy board oversight. 503B outsourcing facilities produce larger batches under FDA-registered cGMP conditions and can ship without patient-specific prescriptions. 503B generally carries higher quality assurance and higher COGS; 503A offers more flexibility.
Do I need a medical director? +
Requirements vary by state. Most states require physician oversight of NPs providing weight-loss care; some require a physical co-location with a medical director; some allow telemedicine supervision. Check your state medical board and nursing board rules before structuring.
What about DEA and scheduled drugs? +
GLP-1 medications are not controlled substances and do not require a DEA registration to prescribe. However, any clinic that also prescribes Schedule III–V appetite suppressants (e.g., phentermine) requires an active DEA registration for the prescriber.

Related